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 Protocol abstract 
Introduction 
 This is a randomized clinical trial to prove bioequivalence between nasonex and a generic 
mometasone fuorate product in patients with seasonal allergic rhinitis. 
  
Methods  
In the study patients with SAR will undergo through a placebo period for 7 days in which 
clinical evaluations will be made twice daily for their nasal symptoms using the tonal nasal 
symptom score. 
After that randomization will follow, and double  blinded, administration of nasonex, generic 
drug and placebo will be given to patients evaluating them with the TNSS twice daily for 2 
weeks. 
 
Outcomes  
The primary objective is to determine whether the  generic mometasone is therapeutically 
equivalent to Nasonex .Secondary objectives is to assess safety of  generic mometasone 
versus Nasonex over the study period and to compare the efficacy of the two mometasone 
containing products with that of placebo. 
 
Conclusion  
The aim of the study is to prove that the generic product is equivalent to the reference one, 
is efficient and is safe for use.  
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 Study title  
A randomized control study to evaluate the bioequivalence of nasonex and a generic 
mometasone fuorate test nasal spray  
Objectives  
The primary objective is to determine whether the  generic mometasone is 
therapeutically equivalent to Nasonex 
Secondary objectives is to assess safety of  generic mometasone versus Nasonex 
over the study period and to compare the efficacy of the two mometasone containing 
products with that of placebo. 
Design and outcomes  
A parallel, multi-centered, double bind, randomized clinical trial will be conducted to 
test the bioequivalence of  nasonex and the generic mometasone fuorate nasal 
spray, and their efficacy. 
In both equivalence and efficacy analysis the groups will be measured by TNSS ,a 
common allergic rhinitis rating system which  uses a four-point scale with signs and 
symptoms  ordered in severity from 0 (no symptoms) to 3 (severe symptoms) 
Equivalence is going to be evaluated by calculating the mean difference of the 
original drug at the end of the randomization period (total 27 measures) from the 
baseline reflecting total nasal symptom score (rTNSS- the mean overall intensity of 
the individual symptoms during the previous 24 hours, measured by the patient in the 
evening),  applying the same calculations for the test drug and see if there is a 
statistical significant difference between them.The test drug should have no 
significant statistical difference from the nasonex (p>0.05). 
Efficacy is going to be evaluated by comparing the mean difference of rTNSS score 
of both treatments with placebo.  
Interventions and Duration   
The duration of the trial will be 3 weeks total ,the first 7 days will be the placebo run 
out period and after that the randomized period will start and last 2 weeks. 
At the randomized periods the participants will be divided in 3 groups in a ratio of 2: 
2:1 , which will correspond to nasonex ,mometasone test nasal spray and placebo 
respectively. 
Clinical evaluations will be made twice daily (AM & PM at the same times daily, 12 
hours apart) throught the placebo run out period and the 14 days of randomized 
treatment period. 
Sample Size and Population   
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672 male and female patients aged 18 years and older with a diagnosis of seasoning 
allergic rhinitis (SAR) and a positive skin-prick test to grass or weed pollen within the 
previous year. 
1.Study objectives  
1.1.Primary endpoint 
1)Therapeutic equivalence between generic mometasone nasal spray and Nasonex. 
1.2Secondary endpoint 
1)Compare the efficacy of 2 mometasone products with that of the placebo 
2)Equivalence between T& R in instantaneous nasal symptom scores (recorded the 
four nasal symptoms intensities at the time of assessment by the patient ,before 
administration of the study medication in the morning) 
3)Comparison of rTNSS score after 7days of treatment 
5)Safety of test mometasone spray versus Nasonex 
2.Background and rationale 
2.1 Background on Condition, Disease, or Other Primary Study Focus 
Allergic rhinitis (AR) is a heterogeneous respiratory disorder that despite its high 
prevalence and its impact on quality of life is often undiagnosed. It is characterized 
by one or more symptoms including sneezing, itching, nasal congestion, and 
rhinorrhea. Many causative agents have been linked to AR including pollens, molds, 
dust mites, and animal dander. Allergic rhinitis can be divided in two categories, 
seasonal and perennial. Seasonal allergic rhinitis (SAR) is fairly easy to identify 
because of the rapid and reproducible onset and offset of symptoms in association 
with pollen exposure.  
Given the troublesome impact of SAR, successful treatment of the condition is of 
particular importance. In clinical practice, the commonly used anti-inflammatory 
agents, such as intranasal steroids (INS), leukotriene-receptor antagonists, and 
antihistamines, are recommended by the Allergic Rhinitis and its Impact on Asthma 
(ARIA) guidelines as the first-line choice for treating AR. 
 INS are undoubtedly effective and safe anti-inflammatory agents, which work by 
controlling the rate of protein synthesis through binding to a single glucocorticoid 
receptor.  
Mometasone furoate is a synthetic corticosteroid which has been evaluated for 
intranasal use in the treatment of adults and children with allergic rhinitis. In several 
large, well-controlled clinical trials, mometasone furoate 200 micrograms 
administered once daily as an aqueous intranasal spray was significantly more 
effective than placebo in controlling the symptoms associated with moderate to 
severe seasonal allergic rhinitis. Mometasone furoate was as effective as twice-daily 
beclomethasone dipropionate and slightly more effective than once-daily oral 
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loratadine in the treatment of seasonal allergic rhinitis. Mometasone furoate was also 
as effective as twice-daily beclomethasone dipropionate or once-daily budesonide, 
and significantly more effective than placebo in the prophylaxis of seasonal allergic 
rhinitis. The overall incidence of adverse events is similar to placebo.  
2.2 Study Rationale  
2.2.1 Generic versus branded mometasone  
2.2.1.1 Scope 
During the past years an increasing number of generic corticosteroids were 
introduced, in numerous countries. For generic drugs the EMEA/CBG guidelines 
require a bioequivalence study in which the pharmacokinetic profile and the clinical 
efficacy of the brand formulation (i.e. mometasone) is compared to the reference 
generic product. Based on bioequivalence the generic product is expected to have 
the same clinical efficacy as the brand formulation.   
2.2.1.2 Literature overview 
According to the literature, Mometasone furoate is a well tolerated intranasal 
corticosteroid with minimal systemic activity and an onset of action of < or = 7 hours. 
It is effective in the prophylaxis and treatment of seasonal allergic rhinitis and the 
treatment of perennial allergic rhinitis in patients with moderate to severe symptoms. 
Extensive experience in both clinical trials and the clinical practice setting has firmly 
established the efficacy and good tolerability profile of intranasal mometasone 
furoate in children and adults with SAR. 
 The test mometasone is efficacious in the treatment of SAR in adults and shows a 
favorable safety profile. The results indicate that the test mometasone is 
therapeutically equivalent to the reference mometasone. 
The first generic version of mometasone furoate monohydrate (Nasonex nasal spray) 
has been approved by the FDA, according to the drug's manufacturer in March 22, 
2016. (announced in NEJM) 
 
3.Study design 
 
Type/design of trial: parallel study, double blinded  
 
Primary endpoint :Therapeutic equivalence between generic mometasone and 
Nasonex 
Secondary endpoint :Compare the efficacy of the two mometasone products with 
that of the placebo, the equivalence between T& R in instantaneous TNSS scores, 
compare the rTNSS score after 7days of treatment (50% of the randomized period) 
and also to test the safety of test mometasone spray versus Nasonex. 
Study population and sample size:  
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672 male and female patients aged 18 years old and older with a diagnosis of SAR 
and a positive skin-prick test to grass or weed pollen within the previous year. 
Study location:  
out -patient, multi-centered study   
 
Duration of screening period and follow-up:  
The screening period will be one week where the placebo drug will be administered 
and afterwards the randomization will occure and the follow up period is going to last 
for 2 weeks.  
 
Intervention period: Clinical evaluations will be made twice daily (AM & PM at the 
same times daily, 12 hours apart) throught the placebo run out period and the 14 
days randomized treatment period 
Description of intervention and administration:  
It is a parallel group study of 3 weeks duration totally. 
It will start with a 7 day placebo run in period to establish a baseline of mean TNSS 
score and to identify placebo responders  
Placebo responders  will be excluded from the study 
 
After that randomization will follow, and double  blinded, administration of nasonex, 
generic drug and placebo will be given to patients with a ratio 2:2:1 (nasonex:generic: 
placebo respectively) 
. 
Clinical evaluations will be made twice daily (AM & PM at the same times daily, 12 
hours apart ) throught the placebo run out period and the 14 days randomized 
treatment period 
Table 1 :Study design 
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4.Selection and enrollement of participants  
 
Inclusion Criteria: 
1. Age: 18 years of age or older. 
2. Signed informed consent form. For patients under the age of majority, the 
parent or legal guardian should sign the consent form and the child will be 
required to sign a patient "assent" form. 
3. Sex: Male and/or non-pregnant, non-lactating females. 
o All women of childbearing potential must have a negative serum pregnancy 
test performed within 21 days prior to the start of the study and must be using 
a medically acceptable form of birth control. 
o Women will not be considered of childbearing potential if one of the following 
is reported and documented on the medical history: 
a)postmenopausal with spontaneous amenorrhea for at least six months and 
a serum FSH levels >40mIU/ml, or 
b)bilateral oophorectomy with or without a hysterectomy and an absence of 
bleeding for at least 6 months, or 
c)total hysterectomy and an absence of bleeding for at least 3 months. 
4. History of seasonal allergic rhinitis of at least 2 years duration 
5. Positive response to skin allergen testing to the relevant seasonal allergen 
(e.g. grass/tree/ragweed) for that sites geographical area within 14 months or 
at the time of study entry. Wheal size must be greater than or equal to (≥) 5 
mm larger in diameter than diluent control via prick testing or greater than or 
equal to 7 mm larger in diameter than diluent control via intradermal testing. 
6. Clinically active status (symptomatic) at both screening and baseline. The 
total nasal symptom score is to be greater than or equal to 6 on a 0-3 
symptom scale with a score of at least 2 (moderate severity) for each of nasal 
congestion/stuffiness and one other nasal symptom score (rhinnorea, nasal 
itching, sneezing), and an overall disease rating of moderate or severe (e.g. 
total score of six or greater). 
7. Weight: Age appropriate weight. BMI not to exceed 40 kg/m2 
8. Tobacco Use: non-tobacco using for at least 3 months prior to study initiation. 
9. Capable of providing informed consent or assent. 
10. All subjects should be judged by the Principal Investigator or Medical Sub-
Investigator as otherwise normal and healthy and free of clinically significant 
disease except for signs and symptoms of rhinoconjunctivitis that would 
interfere with the study schedule or evaluation of SAR during a pre-study 
medical evaluation performed within 21 days of the initial dose of study 
medication which will include: 
a)normal or non-clinically significant physical examination including nasal 
passage evaluation, including vital signs (pulse, temperature, respiration rate, 
blood pressure) 
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 b)within normal limits or non-clinically significant laboratory evaluation results 
(unless otherwise specified) for the following tests: Serum Chemistries 
(Sodium,Albumin,Blood urea nitrogen (BUN), Potassium ,Uric Acid, Aspartate 
aminotransferase (AST),Chloride, Iron, Alanine aminotransferase 
(ALT),Calcium ,Total Cholesterol, Alkaline Phosphatase, Creatinine ,Glucose, 
Phosphate, Total Protein, Triglycerides, Total Bilirubin),  Fasting or non-
fasting may be performed based on clinical judgment, Hematology tests 
(Platelet Count, White blood cell count w/differential, Hemoglobin, Hematocrit, 
Red Blood Cell count), Urinalysis, Protein, pH, Specific Gravity,Appearance - 
Microscopic Examination (to be performed if urine dipstick is positive),normal 
or non-clinically significant 12-lead ECG, negative urine drug screen including 
amphetamine, barbiturates, benzodiazepines, cannabinoid (marijuana), 
methadone, cocaine, opiates, and phencyclidine unless legal prescribed or 
allowed by state/federal law. 
Additional tests and or examinations may be performed, if judged necessary by the 
Principal Investigator or Medical Sub-Investigator. 
Exclusion Criteria: 
1. Institutionalized subjects. 
2. Individuals who have a rTNSS score of 6 or greater at the start of the placebo 
run-in period but who on the randomization day (i.e. Study Day 8) no longer 
meet the requirement (i.e. score <6) prior to randomization, or who have a 
score less than 2 for Stuffiness/Congestion, or who have a score of less than 
2 for all 3 of the remaining Nasal Symptoms will result in discontinuation of 
the subject from the study and the subject will not receive randomized 
treatment. The rTNSS score assessed on the randomization day (i.e. Study 
Day 8) will be an average of the scores from the preceding 7 scoring time 
points. Since randomization occurs on Day 8, then the average total score of 
the placebo run-in phase will include the rTNSS scores from Study Day 5 (AM 
& PM), Study Day 6(AM & PM), Study Day 7(AM & PM), and Study Day 
8(AM). 
3. Females who are pregnant or nursing. 
4. History of alcohol and/or drug abuse within 1 year of subject randomization. 
5. Medications: 
*All routinely used (e.g. daily) concomitant medications taken for any co-
morbidity (i.e. hypertension, high triglycerides, diabetes, etc) will be 
documented. Subjects receiving concomitant medications should be on stable 
doses of the medications (defined as no change in the dose for at least 3 
months and the dose is not anticipated to change during the study). 
*Subject is dependent on nasal, oral, or ocular decongestants, or anti-
inflammatory agents; as determined by the principal investigator, or diagnosis 
of rhinitis medicamentosa. 
*Subjects who cannot tolerate nasal sprays. 
*Use of intranasal or systemic first generation antihistamines, leukotriene 
receptor antagonists (i.e. montelukast) or other nasal decongestants within 3 
days of enrollment. 
*Use of intranasal cromolyn within 14 days of enrollment. 
*Use of intranasal or systemic second-generation antihistamines (e.g. 
fexofenadine, loratadine, desloratadine, cetirizine) within 10 days of 
enrollment. 
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*Use of any tricyclic anti-depressant within 30 days of enrollment. 
*Use of any ophthalmic steroids within 14 days or nasal, inhaled, or systemic 
steroids within 30 days of the study start. Super or high potency topical 
steroids should not be used during the study. The use of low potency topical 
corticosteroids will be allowed (e.g. over-the-counter 1% hydrocortisone). 
*Use of chronic medication that could affect the course of seasonal allergic 
rhinitis. 
6. Diseases 
- Subjects who have had an upper respiratory tract or sinus infection requiring 
antibiotic therapy within thirty days days of enrollment, or who have had a 
viral upper respiratory tract infection within 30 days prior to the screening visit. 
History of recurrent sinusitis or chronic purulent postnasal drip 
- History of any significant cardiovascular, hepatic, renal, pulmonary, 
hematologic, gastrointestinal, endocrine, immunologic, dermatologic, 
neurologic, psychological, musculoskeletal disease, malignancies or other 
significant medical illness, which in the judgement of the principal investigator 
could interfere with the study or require medical treatment that would interfere 
with the study. 
- Clinical evidence of large nasal polyps, marked septal deviation, or any 
other nasal structural abnormality that may significantly interfere with nasal 
airflow, as determined by the principal investigator. 
-History of asthma over the previous two years that required chronic therapy 
with inhaled or systemic corticosteroids. Occasional acute or mild exercise 
induced asthma will be allowable on the condition that the treatment of the 
attacks is restricted to β-agonists only. 
-Recent exposure (within 30 days) or was at risk of being exposed to chicken 
pox or measles. 
-Previous seasonal allergic rhinitis or perennial allergic rhinitis that has proven 
unresponsive to steroid therapy. 
-Subjects with infectious rhinitis or atrophic rhinitis. 
-History of anaphylaxis and/or other severe local reactions(s) to skin testing, 
as determined by the Principal Investigator or Medical Sub-investigator. 
-Symptoms of common cold or upper respiratory infection or other acute 
illness at the screening or baseline visit. 
-Treatment for oral Candidiasis within 30 days of starting the study or a 
current oral Candidiasis infection 
-History of posterior subcapsular cataracts. 
-History of tuberculosis, or with the presence of uncontrolled glaucoma, 
cataracts, ocular herpes simplex, conjunctivitis or other eye infection not 
related to the diagnosis of seasonal allergic rhinitis. 
-Presence of untreated fungal, bacterial, or systemic viral infections within the 
previous 30 days. 
7. Recent history of nasal septal surgery, nasal septal perforation (ulceration) or 
recent nasal injury that has not completely healed. 
8. Any reason which, in the opinion of the Principal Investigator or Medical Sub-
Investigator, would prevent the subject from safely participating in the study. 
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9. Travel outside the geographical region of pollen (local area) for more than 2 
consecutive days or 3 days in total throughout the trial. 
10. Anticipation of clinically significant symptoms due to perennial allergens (e.g. 
dust mite, molds, animal dander) prior to the anticipated start of the relevant 
seasonal allergy season. In other words anticipated flare of perennial allergy 
symptoms immediately prior to or during seasonal allergic rhinitis flare. 
11. Previous participation in this study, or the patient is a member of the 
investigational study site staff or a member of the family of the investigational 
study site staff. 
12. Not on stable dose of immunotherapy for at least 3 months prior to 
randomization and during trial. 
13. Desensitization therapy to a seasonal allergen that is responsible for the 
subject's allergic rhinitis that is initiated or changed within the previous six 
months. 
14. Subjects who have received an investigational drug within 30 days prior to the 
initial dose of study medication. 
History of allergy/hypersensitivity to mometasone, other related products (i.e 
corticosteroids), or any of the inactive ingredients. 
5. STUDY INTERVENTIONS   
Before subjects may be entered into the study, a copy of the site’s written 
independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent forms is required. All subjects must personally sign 
and date the consent form before enrollment.  
5.1 Interventions, Administration, and Duration 
 
All patients will be treated in an out-patient setting with placebo for 1 week and then 
after the exclusion of placebo responders they will be given one of the 3 products 
(placebo,nasonex,mometasone fuorate test nasal spray) 
The drug will be administered  with the usual recommended dose is two actuations 
(50 micrograms/actuation) in each nostril once daily (total dose 200 micrograms) 
Prior to administration of the first dose, shake container well and actuate the pump 
10 times (until a uniform spray is obtained). 
Clinical evaluations will be made twice daily (AM & PM at the same times daily, 12 
hours apart) throught the placebo run out period and the 14 days randomized 
treatment period. 
5.2 Procedures for randomization 
 Randomisation codes will be assigned strictly sequentially as volunteers become 
eligible for randomisation. A randomisation list, with randomisation codes and 
treatments will be produced by Quintiles using a randomisation  program online 
(https://www.randomizer.at ) 
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At the randomization procedure the ratio of the 3 drugs will be 2:2:1 for 
nasonex,mometasone fuorate test drug and placebo respectively. 
5.3 Handling of Study Interventions 
Randomization will be via a central scheme with an interactive voice response 
system. During the randomized treatment period, the study will be double blinded. All 
nasal sprays will be contained within a plastic cover, being the same shape, size, and 
color for all three products ensuring blinding of all parties. There is going to be no 
difference in odor between the products. 
5.4 Procedures for handling subjects incorrectly enrolled or randomized 
Volunteers who fail to meet the inclusion/exclusion criteria should not, under any 
circumstances, be enrolled or receive study medication.  There can be no exceptions 
to this rule. When a volunteer does not meet the selection criteria, is randomised in 
error, and this is identified before dosing, the volunteer should be withdrawn from the 
study.  A discussion should occur between the responsible ENT physician and the 
Investigator regarding whether a replacement should be considered.  The ENT is to 
ensure all such decisions are appropriately documented. If a volunteer who does not 
meet the selection criteria has been dosed before the error is identified, the volunteer 
should be advised to continue assessments to ensure their safety, and the ENT  
should be informed of the error.  The volunteer should be withdrawn from the study 
prior to further dosing.  
5.5 Labelling 
 Labels will be prepared in accordance with local regulatory guidelines.The label will 
include the following information: 
Name of sponsor (….) • Study drug(s) dosage form, route of administration, and 
quantity of dosage units • Study code • Order number (to identify the contents and 
packaging operation) • Directions for use (for oral use) • The period of use, eg, expiry 
date • Storage conditions • For clinical trial use only 
5.6 Storage 
 All study drugs should be kept in a secure place under appropriate storage 
conditions.  The label on the container specifies the appropriate storage.  
Mometasone fuorate nasal sprays must not be stored above 25°C and do not freeze. 
 
5.7 Accountability 
 The study drug provided for this study will be used only as directed in the study 
protocol. The study personnel will account for all study drugs dispensed to and 
returned from the volunteer. At the end of the study, study site personnel will account 
for all study drugs received at the site, unused study drugs and for appropriate 
destruction.  Destruction must not take place unless principal investigator  has 
approved it.  Certificates of delivery and destruction must be signed. 
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6.Study procedures  
6.1 Description of Evaluations  
6.1.1 Study Visit Definitions   
The screening date is defined as the date the informed consent is signed.   
It will start with a 7 day placebo run in period to establish a baseline and to identify 
placebo responders  
Enrolment date is defined as the date of randomization.  
Day 1 is defined as the day that the randomization begins.   
A study week  is defined as a calendar week. 
Placebo run in period : reflective AM &PM scoring on days 5,6,7 of the placebo run in 
period and AM scoring (prior to drug dosing) on Day 1 of the 14 day randomized 
treatment period, resulting in 7 total AM and PM ratings. 
Placebo responders would be identified based on the mean total nasal symptom  
score (TNSS) over the 7 total AM and PM ratings.  
The study protocol would state the minimum qualifying reflective TNSS for enrollment 
at screening, and the same minimum qualifying TNSS would be met based on the 
mean of the 7 total AM and PM ratings prior to each patient’s  participation in the 
randomized portion of the study.  
Symptom scores during the randomized treatment period would consist of the PM 
score on Day 1, and the 26 AM and PM ratings on Days 2 to 14, resulting in 27 total 
ratings.   
7. REMOVAL AND REPLACEMENT OF SUBJECTS   
7.1 Removal of Subjects  
Subjects have the right to withdraw fully or partially from the study at any time and for 
any reason without prejudice to his or her future medical care by the physician or at 
the institution.   
Withdrawal of full consent for a study means that the subject does not wish to receive 
further investigational treatment and does not wish to or is unable to continue further 
study participation. Any subject may withdraw full consent to participate in the study 
at any time during the study. The investigator will discuss with the subject the most 
appropriate way to withdraw to ensure the subject’s health.   
Withdrawal of partial consent means that the subject does not wish to take the 
investigational product any longer but is still willing to collaborate in providing further 
data by continuing on study (eg, participate in all subsequent study visits or 
procedures). Subjects may decline to continue receiving the investigational product 
at any time during the study. These subjects, as well as those who have stopped 
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receiving the investigational product for other reasons (eg, investigator or sponsor 
concern) will be asked to participate in one, last visit for completion of the data.    
 Reasons for removal from the investigational product or study might include:   
- administrative decision by the investigator   
- ineligibility  
- significant protocol deviation  
- patient noncompliance  
- adverse event   
- withdrawal of consent   
 Should a subject (or a legally acceptable representative) request or decide to 
withdraw from the study, all efforts will be made to complete and report the 
observations as thoroughly as possible up to the date of withdrawal. If withdrawn 
consent is recorded as the reason for either ending investigational product or ending 
study an attempt should be made to determine the possible underlying reason for 
withdrawing consent, if applicable, and to record that as the primary reason. All 
information should be reported.   
8. SAFETY ASSESSMENTS   
8.1 Section 10 WMO event  
In accordance to section 10, subsection 1, of the WMO,  the investigator will inform 
the subjects and the reviewing accredited METC if anything occurs, on the basis of 
which it appears that the disadvantages of participation may be significantly greater 
than was foreseen in the research proposal.  The study will be suspended pending 
further review by the accredited METC, except insofar as suspension would 
jeopardise the subjects’ health. The investigator will take care that all subjects are 
kept informed.  
 
8.2 Adverse Events  
An adverse event is defined in the International Conference on Harmonisation (ICH) 
Guideline for Good Clinical Practice as “any untoward medical occurrence in a 
patient or clinical investigation subject administered a pharmaceutical product and 
that does not necessarily have a causal relationship with this treatment.” (ICH E6:1.2)   
This definition of adverse events also includes worsening of a pre-existing medical 
condition. Worsening indicates that the pre-existing medical condition (eg, cancer, 
diabetes, migraine headaches, gout) has increased in severity, frequency, or duration 
of the condition or an association with significantly worse outcomes. 
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Interventions for pretreatment conditions (eg, elective cosmetic surgery) or medical 
procedures that were planned before study enrollment are not considered adverse 
events  
Safety and tolerability assessments are going to  include the recording of all AEs, 
vital signs, body weight, physical examination, nasal examination, and routine 
laboratory parameters (including 12-hour urinary-free cortisol and creatinine in a 
subgroup of patients). Information recorded on AEs included severity, relationship to 
study drug, and duration will be noted. 
The investigator is responsible for reviewing laboratory test results and determining 
whether an abnormal value in an individual study subject represents a change from 
values before the study. In general, abnormal laboratory findings without clinical 
significance (based on the investigator's judgment) should not be recorded as 
adverse events; however, laboratory value changes requiring therapy or adjustment 
in prior therapy are considered adverse events. 
Side effects  
Epistaxis is generally self-limiting and mild in severity, and occurs at a higher 
incidence compared to placebo (5%) as described in the literature, but at a 
comparable or lower incidence when compared to the active control nasal 
corticosteroids studied (up to 15%) as reported in clinical studies for allergic rhinitis.   
Systemic effects of nasal corticosteroids may occur, particularly when prescribed at 
high doses for prolonged periods. These effects are much less likely to occur than 
with oral corticosteroids, and may include Cushing’s syndrome, Cushingoid features, 
adrenal suppression, growth retardation in children and adolescents, cataract, 
glaucoma and more rarely, a range of psychological or behavioural effects including 
psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression 
(particularly in children).  
In contrary to systematic corticosteroids, there is no evidence of hypothalamic-
pituitary-adrenal (HPA) axis suppression following prolonged treatment with 
mometasone fuorate Nasal Spray. 
 
8.3 Serious Adverse Events   
A serious adverse event (SAE) is defined as an adverse event that   
• is fatal   
• is life threatening (places the subject at immediate risk of death)   
• requires in-patient hospitalization or prolongation of existing hospitalization   
• results in persistent or significant disability/incapacity   
• is a congenital anomaly/birth defect   
14 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:31:44 EEST - 137.108.70.13
• other significant medical hazard   
A hospitalization meeting the regulatory definition for “serious” is any inpatient 
hospital admission that includes a minimum of an overnight stay in a health care 
facility. Any adverse event that does not meet one of the definitions of serious (eg, 
emergency room visit, outpatient surgery, or requires urgent investigation) may be 
considered by the investigator to meet the “other significant medical hazard” criterion 
for classification as a serious adverse event. Examples include allergic 
bronchospasm, convulsions, and blood dyscrasias 
8.4 Reporting Procedures  
The investigator is responsible for ensuring that all adverse events (as defined in 8.1 
and 8.2) observed by the investigator or reported by subjects are collected and 
recorded in the subjects’ medical records. These adverse events will include the 
following:   
The following adverse event attributes must be assigned by the investigator: adverse 
event diagnosis or syndrome(s) (if known, signs or symptoms if not known); event 
description (with detail appropriate to the event); dates of onset and resolution; 
severity; assessment of relatedness to investigational product and action taken.  
If applicable, the relationship of the adverse event to the investigational product will 
be assessed by means of the question: “Is there a reasonable possibility that the 
event may have been caused by the investigational product?” The investigator 
should respond to this question with either Yes or No.   
Medically significant adverse events considered related to the investigational product 
by the investigator will be followed until resolved or considered stable.   
It will be left to the investigator’s clinical judgment to determine whether an adverse 
event is related and of sufficient severity to require the subject’s removal from 
treatment or from the study. A subject may also voluntarily withdraw from treatment 
due to what he or she perceives as an intolerable adverse event. If either of these 
situations arises, the subject should be strongly encouraged to undergo an end-of-
study assessment and be under medical supervision until symptoms cease or the 
condition becomes stable.  
 The expedited reporting will occur not later than 15 days after the investigator has 
first knowledge of the adverse reactions. For fatal or life threatening cases the term 
will be maximal 7 days for a preliminary report with another 8 days for completion of 
the report.   
9. STATISTICAL CONSIDERATIONS   
Calculating the sample size 
The formula for calculating the sample size for a single mean at P=0.05 with power 
90% is :  
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 Were s : 2.4 (from previous studies : Kuna et al) 
a minimal clinically important difference : estimated threshold equal to 30% of the 
maximum total nasal symptom score. (the TNSS can range from 0 to 12 or 0 to 24 
according to the study design) (from previous studies Meltze et al 2016) 
n=(2,4/0.3)2 (10.5)2 = 672 patients will be needed for the trial  
Statistical analysis  
We will have 27 results for reflecting score (mean for each patient) :Estimate 
difference from baseline  
Equivalence analysis : compare the two mometasone products  
The primary endpoint will be the reflective score  
The statistical method that will be used is one way ANOVA test to compare the 
means for the 3 groups (a:placebo b:generic  c:nasonex) and then post hoc to see 
the difference between the groups  
The difference between the nasonex and generic will provide us the equivalence. 
The test drug should have no significant difference from the nasonex (p>0.05). 
After that we have to find he maximum tolerated variation (a minimal clinically 
important difference : estimated threshold)  which by the literature is equal to 30% of 
the maximum total nasal symptom score. 
In the European protocol (according to EMA) we must impose an equivalence 
limit (Δ), and the 95% Confidence Interval of Test-Reference should be included 
within the limits (-Δ, +Δ) 
Consequently the equivalence limit (D) is 0.3 and the 95% Confidence Interval of 
Test-Reference that we will find should be included within the limits (-0.3, +0.3) in 
order to prove that the hypothesis of equivalence is right. 
 
In the American protocol (according to FDA) we will make a logarithmic transform 
of the data (the mean difference of our results) and then we will do the ANOVA test,  
the 90% CI of Test/Reference should be included within the limits (80%, 125%), 
based on our  ln-transform data in order to prove that the hypothesis of equivalence 
is right. 
After establishing the equivalence with the same statistical method we will calculate 
the parameters for the secondary outcomes  
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The difference between each group and placebo will provide as the efficacy and it is 
going to be calculated by ANOVA. 
The equivalence in the instantaneous score (by comparing the mean difference of 
the test and reference products) will be also calculated by the same way. 
Compare  the equivalence of the test and reference product at the 50% of time, by 
calculating the difference from the baseline of the scores at day 7, and then make a 
comparison using a t test. 
For the adverse effects and safety ,for each treatment (test drug ,reference drug and 
placebo ) the amount treatment-emergent adverse events will be measured and 
compared using ANOVA  
10. PARTICIPANT RIGHTS AND CONFIDENTIALITY   
10.1 Institutional Review Board (IRB) Review   
 This protocol and the informed consent document and any subsequent modifications 
will be reviewed and approved by the ethics committee responsible for oversight of 
the study.  
10.2 Informed Consent Form  
 The PI or delegate will: 
 • Ensure each volunteer is given full and adequate oral and written information about 
the nature, purpose, possible risk and benefit of the study  
• Ensure each volunteer is notified that they are free to discontinue from the study at 
any time   
• Ensure that each healthy volunteer is given the opportunity to ask questions and 
allowed time to consider the information provided  
• Ensure each healthy volunteer provides signed and dated informed consent before 
conducting any procedure specifically for the study 
 • Ensure the original, signed ICF(s) is/are stored in the Investigator’s Study File  
• Ensure a copy of the signed ICF is given to the healthy volunteer 
 • Ensure that any incentives for healthy volunteers who participate in the study as 
well as any provisions for healthy volunteers harmed as a consequence of study 
participation are described in the ICF that is approved by an EC. 
 
11. ETHICAL CONSIDERATIONS  
All subjects participating in this study will be informed in writing and verbally about 
the purpose and procedures of the study by the investigator or research coordinator. 
All subjects will provided an informed consent form describing this study and 
providing sufficient information for subjects to make an informed decision about their 
participation in this study.  This consent form will be submitted with the protocol for 
review and approval by the Ethical Committee.  The formal consent of a subject (by 
signing the approved consent form) must be obtained before that subject undergoes 
any study procedure.  The consent form must be signed and dated by both the 
subject and the investigator. The subject will be provided with a signed copy of the 
informed consent.   
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Subjects’ confidentiality will be ensured by the investigator and will be maintained by 
the following procedures:  
Subjects will be coded by their initials and a specific study number. This code will be 
used on all study forms or other documents with regard to this study.  
The individual participants number is based on the year and month at entrance of the 
study, with the adaptation of number 1 to 30.  
Documents that are needed in compliance with Federal regulations/ICH GCP 
guidelines e.g. signed informed consents, subjects identification list, will be kept at a 
secure location and in strict confidence by the investigator.  
Subjects are free at all time to discontinue participating in the study, without providing 
any reason for discontinuation.  
An independent physician is available for questions of the subjects.   
Subjects will be informed about the outcome of the trial.  
All data collected will be kept for 15 years after completion of the study 
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